Buscar ubicaciones
Para conocer los horarios, visitas sin turno y citas.EGFR Oncology FISH
CPT:
Contact CPT coding department at 800-222-7566, ext. 6-8400.
|
|
|
Contact CPT coding department at 800-222-7566, ext. 6-8400. |
Synonyms
- Brain Cancer
- Breast Cancer
- Lung Cancer
Special Instructions
There will be an additional charge for processing paraffin block samples or for samples that require culture.
Expected Turnaround Time
3 - 5 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Information
Related Documents
Specimen Requirements
Specimen
Three slides of 4- or 5-micron FFPE sections with tumor. Blood or paraffin block (acceptable at an additional charge).
Volume
Three slides of 4- or 5-micron thick with tumor or 10 mL blood (adult), 5 mL blood (pediatric)
Minimum Volume
Two slides of 4- or 5-micron thick with tumor or 5 mL blood (adult), 1 mL blood (pediatric)
Container
Green-top (sodium heparin) tube; pediatric Vacutainer® is optimal
Collection
Transport to the testing lab at room temperature; use a cool pack or LabCorp transport kit. Do not allow sample to freeze.
Storage Instructions
Maintain specimen at room temperature.
Causes for Rejection
Broken or dirty slides; excessive cellular debris or stained slides; decalcified bone cores; frozen specimen; no tumor submitted
Test Details
Use
Confirmation/identification of cancer-related alterations (for lung and brain cancer)
Limitations
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
Methodology
Fluorescence in situ hybridization (FISH)
Additional Information
High EGFR copy number or ratio of EGFR:control >2.0 detected by FISH has been shown to correlate with response, progression-free survival, and overall survival after treatment with EGFR TKIs in patients with non−small-cell lung cancer (NSCLC).1
Footnotes
1. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005 May 4; 97(9):643-655.17317677
LOINC® Map
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf